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Background: Contrast medium used for radiologic tests can decrease renal function. However there have been few
studies on contrast-associated acute kidney injury in intensive care unit (ICU) patients. The objective of this study
was to evaluate the incidence, characteristics, and outcome of contrast-associated acute kidney injury (CA-AKI) patients
using the Risk, Injury, Failure, Loss, and End-stage kidney disease (RIFLE) criteria in critically ill patients in the ICU.
Methods: We conducted a retrospective study of adult patients who underwent contrast-enhanced radiologic tests
from January 2011 to December 2012 in a 30-bed medical ICU and a 24-bed surgical ICU.
Results: The study included 335 patients, and the incidence of CA-AKI was 15.5%. The serum creatinine and estimated
glomerular filtration rate values in the CA-AKI patients did not recover even at discharge from the hospital compared
with the values prior to the contrast use. Among 52 CA-AKI patients, 55.8% (n = 29) had pre-existing kidney injury and
44.2% (n = 23) did not. The CA-AKI patients were divided into risk (31%), injury (31%), and failure (38%) by the
RIFLE classification. The percentage of patients in whom AKI progressed to a more severe form (failure, loss,
end-stage kidney disease) increased from 38% to 45% during the hospital stay, and the recovery rate of AKI
was 17% at the time of hospital discharge. Because the Acute Physiology and Chronic Health Evaluation (APACHE) II
score was the only significant variable inducing CA-AKI, higher APACHE II scores were associated with a higher risk of
CA-AKI. The ICU and hospital mortality of patients with CA-AKI was significantly higher than in patients without CA-AKI.
Conclusions: CA-AKI is associated with increases in hospital mortality, and can be predicted by the APACHE score.
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Keywords: Contrast-associated acute kidney injury, Intensive care unit, RIFLE classification* Correspondence: NSWKSJ@yuhs.ac
1Department of Anesthesiology and Pain Medicine, Anesthesia and Pain
Research Institute, Yonsei University College of Medicine, 50 Yonsei-ro,
Seodaemun-gu, Seoul 120-752, Republic of Korea
Full list of author information is available at the end of the article
© 2015 Kim et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Kim et al. BMC Anesthesiology  (2015) 15:23 Page 2 of 8Background
Despite advances in supportive care measurements,
acute kidney injury (AKI) remains one of the major
causes of mortality and morbidity in critically ill patients
in intensive care units (ICUs) [1]. There are many fac-
tors in ICU patients that can impair renal function, such
as septicemia, hypotension, and the use of drugs causing
renal dysfunction [2]. In these factors, contrast agents
have been shown to be one of the significant causes of
AKI; however, their use is unavoidable in the diagnosis
and treatment of this patient population, and many stud-
ies have investigated this complication. Seelinger et al.
[3] reported that mechanisms of renal injury include dir-
ect cytotoxic effects, autocrine and paracrine factors that
perturb renal hemodynamics, altered rheological proper-
ties that affect renal hemodynamic and tubule-dynamics,
and regional hypoxia. However, the pathophysiology
underlying contrast-associated acute kidney injury
(CA-AKI) is still not completely understood.
The incidence of CA-AKI in critically ill patients
ranges from less than 2% to 18%, depending on the
study populations and the definition of CA-AKI [4-8]. In
one study, acute renal failure in critically ill patients was
associated with increased use of hospital resources and
increased morbidity and mortality due to the limited re-
sources of the ICU [9]. In addition, with CA-AKI, 64%
mortality was reported in adult ICU patients requiring
renal replacement therapy (RRT) [10].
The RIFLE (Risk, Injury, Failure, Loss, and End-stage
kidney disease [ESKD]) criteria are based on elevated
serum creatinine (SCr) and decreased estimated glom-
erular filtration rate (eGFR) and urinary output (UO)
from baseline; these criteria have been used to define
AKI and classify patients according to the severity of
AKI [11]. The RIFLE classification was developed by the
Acute Dialysis Quality Initiative group in 2004; it includes
the progressive severity classes risk, injury, and failure, as
well as two outcome classes: loss and ESKD [12].
The aim of this study was to evaluate the incidence of
CA-AKI using the RIFLE criteria, the clinical outcome
of renal function, and risk factors for CA-AKI in ICU
patients from 2011 to 2012. Additionally, we assessed
the relationship of CA-AKI to the outcome of ICU pa-
tients, such as the requirement for RRT, the duration of
stay and mortality rate in the ICU and hospital.
Methods
We conducted a retrospective study with patients who
received CM for computed tomography (CT) or mag-
netic resonance imaging (MRI) from January 2011 to
December 2012 in a 30-bed medical ICU and a 24-bed
surgical ICU at a single university-affiliated hospital.
This study was approved by the Institute of Research
Committee at Severance Hospital, Yonsei UniversityHealth System (IRB number: 4-2012-0922) and regis-
tered as a clinical trial (NCT01807195). Informed con-
sent from patients and families was waived due to the
retrospective nature of the review of electronic hospital
records.
Data collection
We collected the following variables from patients ex-
cluding those under 18 years of age.
– We collected baseline patients’ characteristics: age,
gender, body height and weight, Acute Physiology
and Chronic Health Evaluation (APACHE) II score,
admission categories (medical or surgical), admission
diagnosis (cardiovascular, respiratory, neurologic,
renal, operation, etc.), and co-morbidities
(hypertension, diabetes mellitus, cardiac disease,
liver disease, respiratory disease, kidney disease).
– Blood urea nitrogen (BUN), SCr and eGFR values
were measured the day of the radiologic study,
immediately prior to the administration of CM
(baseline), and thereafter at 24 hours, 48 hours,
72 hours, and on the ICU discharge day and
hospital discharge day. UO was also measured at the
same time periods.
– We investigated variables suspected of being risk
factors for CA-AKI based on previous studies: the
type of radiologic tests, the volume of CM, mean
arterial pressure (MAP) and hemoglobin (Hb)
values at the point of contrast use, preventive measures
(N-acetylcysteine and isotonic crystalloid) before and
after CM administration, whether RRT was applied,
and whether diuretics were used after contrast
administration.
Outcomes
The primary outcomes were the incidence of CA-AKI
and the progress of CA-AKI using the RIFLE classifica-
tion (Table 1) [11]. We defined CA-AKI with the RIFLE
criteria as a relative increment in SCr of ≥ 50%, or a rela-
tive decrement in eGFR of ≤ 25% from baseline, or an
episode of oliguria lasting ≥ 6 h within 48 to 72 hours
following contrast administration. Secondary outcomes
were risk factors for CA-AKI and the requirement for
RRT, length of stay in the ICU and hospital after con-
trast use, and mortality rate in the ICU and hospital.
Statistical analysis
The occurrence of CA-AKI was examined, and patients
developing CA-AKI were compared with a group of pa-
tients who did not develop AKI after CM use. For con-
tinuous variables, all statistical values were expressed as
the mean (standard deviation), or median (minimum-
maximum). T-test and Mann–Whitney U test were used
Table 1 RIFLE (Risk, Injury, Failure, Loss, End-stage kidney disease) criteria for the definition of acute kidney injury
RIFLE category GFR criteria Urine output criteria
Risk Increased serum creation × 1.5 or decreased of GFR >25% Urine output <0.5 mL/kg/hr for 6 hrs
Injury Increased serum creatinine × 2 or decrease of GFR >50% Urine output <0.5 mL/kg/hr for 12 hrs
Failure Increased serum creatine × 3 or decrease of GFR >75% or serum
creatinine≥ 4 mg/dL
Urine output <0.3 mL/kg/hr for 12 hrs or anuria
for 12 hrs
Loss End-stage kidney
disease
Complete loss of renal function for >4 wks Need for RRT for >3 mos.
GFR, glomerular filtration rate; RRT, renal replacement therapy.
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egorical variables, Chi-square test and Fisher’s exact test
were used. A binary logistic regression model and the
area under the curve (AUC) for the receiver operating
characteristic (ROC) curve were used to analyze the
various factors that affect renal function decline and to
find predictors for the occurrence of CA-AKI. The
change in BUN, SCr, eGFR and UO depending on time
were assessed with repeated measures ANOVA after
Bonferroni’s post hoc test.
The results are shown as adjusted odds ratios with
95% confidence intervals (CI). All p values were two-
tailed, and p value of less than 0.05 was considered sta-
tistically significant. Statistical analyses were performed
using a statistical software package (SPSS, version 20 for
windows, Chicago, IL, USA).
Results
During the 2-year study period, 4561 patients were
admitted to the ICU, and 542 CT and MRI studies
(enhanced and non-enhanced) were performed in
this population. 359 patients received contrast for
radiologic studies, and 24 patients under 18 years of
age were excluded. As a result, 335 patients were
evaluated for CA-AKI. The CM used in this study
was non-ionic and low-osmolality in nature.
1. Demographic data of the patients with and without
CA-AKI
Fifty-two of the 335 patients evaluated (15.5%)
developed CA-AKI. In our study, ICU patients were
admitted to address the respiratory system problems
in CA-AKI and CA-NAKI groups. The APACHE II
scores were significantly higher in patients with than
without CA-AKI (median [interquartile range]: 17
[13-17] vs. 15.5 [13-16,18,19]; p = 0.001, Mann–
Whitney U test). However, there were no significant
differences between the two groups regarding age,
gender, BMI, surgery or not, diagnosis, and underlying
diseases such as existing kidney disease. At the time of
imaging modality using CM, the type of radiographic
tests (CT or MRI), volume of CM used, and
hemodynamic variables such as MAP and Hb values
were not significantly different between the twogroups of patients. There was no difference in preventive
measures for CA-AKI, such as hydration with isotonic
crystalloid and N-acetylcysteine administration within
12 hours before and after CM use (Table 2).
2. Onset and progress of CA-AKI with RIFLE
classification
Onset of CA-AKI occurred 48 hours after contrast
use. At baseline, SCr was 1.17 ± 0.8 mg/dl and GFR
was 74.3 ± 34.9 ml/min/1.73 m2 in these patients. At
48 hours, the values were 1.62 ± 1.09 and 59.9 ± 36.1
respectively (p < 0.001). After 72 hours, the increase
in creatinine level and decrease in GFR peaked
(SCr: 1.83 ± 1.2, GFR: 52.7 ± 33.9; p < 0.001). The
values for SCr and GFR were 1.54 ± 1.25 and 63.4
± 33.6, and 1.42 ± 1.14 and 62.4 ± 29.5 at discharge
from the ICU and hospital, respectively. Using the
RIFLE classification, CA-AKI occurred in 52 patients.
Of these, 29 already had decreased renal function
before contrast administration and 23 (6.9%) had
CA-AKI that developed within 48 hours after contrast
use. The 52 CA-AKI patients were divided into Risk
(31%), Injury (31%), and Failure (38%) at 72 hours
after contrast use and progressed to a more severe
form of injury during their stay in the ICU and hospital.
The severe form of injury (Failure, Loss, and ESKD) of
AKI classification increased from 38% to 45%, and the
recovery rate from AKI was 17% (Table 3) at discharge
from hospital.
3. Risk factor for CA-AKI
The APACHE II score was a significant variable in
CA-AKI, and the AUC (predicted probability) in the
ROC curve was 0.63 (95% CI, 0.54–0.71; p = 0.004, с
statistic) (Figure 1). The cut-off value of the APACHE
II score was less than 17. According to the binary
logistic regression test, higher APACHE II scores
were associated with a higher occurrence risk of
CA-AKI (p = 0.015, Exp (B) = 2.10; 95% CI, 1.15–3.82).
4. Clinical outcomes after CM administration
The RRT rate and the frequency of diuretic use in
patients with and without CA-AKI were similar.
Length of stay (LOS) in the ICU and hospital after
contrast administration was also similar between the
two groups. The ICU mortality of patients with
CA-AKI was significantly higher than in patients
Table 2 Comparison of patients with and without CA-AKI
CA-AKI CA-NAKI OR 95% CI P
(n = 52) (n = 283)
Age (years) 65.5(57–74) 64(53–75) 0.198
Gender 0.9 0.51-1.72 0.877
Male 33(63.5%) 19(36.5%)
Female 175(61.8%) 108(38.2%)
Body height (cm) 162.5(156.1-168.9) 165(158–172) 0.725
Body weight (kg) 62.2(46.9-77.5) 61.5(53.5-69.5) 0.215
ICU unit 1.3 0.70-2.40 0.426
Medical 32(61.5%) 191(67.5%)
Surgical 20(38.5%) 92(32.5%)
Main department General Surgery Internal Medicine 0.552
(n = 19, 36.5%) (n = 117, 41.3%)
Admission diagnosis Respiratory failure Respiratory failure 0.922
(n = 102, 36.0%) (n = 20, 38.5%)
Hypertension 26(55.0%) 126(44.5%) 1.3 0.69-2.25 0.545
Diabetic Mellitus 13(25.0%) 74(26.1%) 0.9 0.48-1.86 1
Cardiac disease 18(34.6%) 75(26.5%) 1.5 0.78-2.76 0.241
Liver disease 12(23.1%) 59(20.8%) 1.1 0.56-2.31 0.714
Respiratory disease 31(59.6%) 143(50.5%) 1.5 0.79-2.64 0.29
Kidney disease 118(41.7%) 29(55.8%) 1.8 0.97-3.20 0.069
Type of tests 0.416
CT 41(78.8%) 197(69.6%)
MRI 11(21.2%) 83(29.3%)
CT & MRI 3(1.1%)
CM volume (ml) 150(125–175) 100(32.5-167.5) 0.09
APACHE II 17(15–19) 15.5(13–18) 0.001
Mean Arterial Pressure (mmHg) 90.5(70.5-110.5) 86(76–96) 0.056
Hemoglobin (g/dl) 9.7(7.4-12.0) 9.4(8.3-10.5) 0.243
Hydration 28(53.8%) 135(47.7%) 1.3 0.71-2.31 0.452
N-Acetylcystein 16(30.8%) 74(26.1%) 1.3 0.66-2.40 0.499
Data are presented as N (%), median (interquartile range).
OR odds ratio, CI confidence interval, P probability value.
CA-AKI contrast-associated acute kidney injury, CA-NAKI contrast-associated no acute kidney injury, ICU intensive care unit, CM contrast medium, CT computed
tomography, MRI magnetic resonance imaging, APACHE II Acute Physiology and Chronic Health Evaluation II.
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CI, 1.34–4.67; p = 0.005, Chi-square test). Hospital
mortality and overall mortality (overall mortality
was calculated from the total expired patients
including readmission and death thereafter) also
were higher in the CA-AKI patients than in patients
without CA-AKI (53.8% vs. 35.7%; OR, 2.1; 95% CI,
1.16–3.82; p = 0.019/ 55.8% vs. 38.2%; OR, 2.04; 95%
CI, 1.12–3.71; p = 0.021, Chi-square test) (Table 4). In
binary logistic regression analysis, CA-AKI was associated
with mortality in the hospital (p=0.015, Exp (B) = 2.10;
95% CI, 1.16–3.82). Figure 2 shows the survival of patients
with and without CA-AKI during the hospital stay. Thesurvival of CA-AKI patients was significantly lower
compared with patients without CA-AKI in the
hospital after CM administration (50% survival
days in the hospital: 61 days vs. 81 days, Log-Rank
test: p = 0.036; Kaplan–Meier plot).Discussion
We evaluated the incidence, characteristics, and out-
come of CA-AKI using RIFLE criteria in the ICU popu-
lation. Because we wanted to determine deterioration of
renal function occurring after the use of contrast agents
regardless of test types, we investigated AKI after using
contrast for either CT or MRI. There have been few
Table 3 The classification of CA-AKI patients by RIFLE criteria from baseline to hospital discharge day in CA-AKI
patients
CA-AKI (N = 52) Baseline Contrast use within 72 h ICU Discharge Hospital discharge
Risk 11(21%) 16(31%) 6(12%) 11(21%)
Injury 4(7%) 16(31%) 10(19%) 9(17%)
Failure 14(27%) 16(38%) 23(44%) 20(39%)
Loss 3(6%)
ESKD
Recovery 13(25%) 9(17%)
Data are presented as N (%).
CA-AKI occurred in 52 patients. 30 patients had acute kidney injury before contrast administration already, by RIFLE criteria. Thus, there were new developed 22
CA-AKI patients within 72 hours after contrast use. Baseline means immediately prior to contrast administration.
ICU discharge: average 6.5 days after contrast use.
Hospital discharge: average 29 days after contrast use.
RIFLE classification.
Risk SCr × 1.5, < 0.5 ml/kg/h × 6 h.
Injury SCr × 2, < 0.5 ml/kg/h × 12 h.
Failure SCr × 3, or SCr ≥ 4 mg/dl with an acute rise > 0.5 mg/dl,< 0.3 ml/kg/h × 24 h or anuria × 12 h.
Loss persistent acute renal failure = complete loss of kidney function > 4 weeks.
ESKD End-stage kidney disease > 3 months.
CA-AKI contrast-associated acute kidney injury, ICU intensive care unit, RIFLE Risk, Injury, Failure, Loss, and End-stage Kidney, SCr serum creatinine, ESKD end stage
kidney disease.
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ICU patients, although studies on the incidence of AKI
in ICUs with the RIFLE classification have been pub-
lished [1,12]. Among recent studies, some have been on
cardiac ICUs after coronary intervention or cardiopul-
monary bypass surgery [13,14]. Additionally, discrepant
results have been reported regarding the incidence and
outcome of CA-AKI in medical or surgical ICUs [4-8].
In our study, the incidence of CA-AKI was 15.5%,
similar to other studies [6,15]. We also found that SCrFigure 1 The ROC curve of the APACHE II score. AUC (predicted proba
p = 0.004, с statistic). Cut-off value of APACHE II score was below 17. ROC
Chronic Health Evaluation II, AUC = area under ROC curve, CA-AKI = contrast-a
value, Cut-off value of APACHE II score > 17.increased and GFR decreased at 48 hours after contrast
use, and peaked at 72 hours. Rashid et al. reported a
CA-AKI rate of 11.5%, defined as both the absolute and
relative increments of plasma creatinine within 48 to
72 hours after intravenous CM injection for CT [6].
Christophe et al. reported a rate of 16.8%, defining
CA-AKI as both the absolute and relative increments
of plasma creatinine within 48 hours. Additionally, the
onset of CA-AKI varied from 2 days to even 1 week
after the procedures, but was usually assessed withinbility of APACHE II score to the CA-AKI) was 0.63 (95% CI: 0.54–0.71,
= receiver operating characteristic, APACHE II = Acute Physiology and
ssociated acute kidney injury, CI = confidence interval, p = probability
Table 4 Morbidity and mortality in ICU patients after contrast administration
CA-AKI CA-NAKI OR 95% CI P
(n = 52) (n = 283)
RRT after CM use 18(34.6%) 69(24.4%) 1.6 0.87-3.09 0.13
Diuretics after CM use 37(71.2%) 168(59.4%) 0.12
CM use after admission (days) 4[0–51] 4[0–80] 0.68
ICU discharge after CM use (days) 6.5[1–124] 7[1–285] 0.83
ICU LOS (days) 14[1.5-26.5] 15[6.5-23.5] 0.98
Hospital discharge after CM use (days) 29[1–262] 27[1–651] 0.69
ICU mortality 21(40.4%) 60(21.3%) 2.5 1.34-4.67 0.01
Hospital Mortality 28(53.8%) 101(35.7%) 2.1 1.16-3.82 0.02
Total mortality 29(55.8%) 108(38.2%) 2.0 1.12-3.71 0.02
Data are presented as N (%), median [minimum-maximum].
OR odds ratio, CI confidence interval, P probability value.
CA-AKI contrast-associated acute kidney injury, CA-NAKI contrast-associated no acute kidney injury, RRT renal replacement therapy, CM contrast medium, ICU inten-
sive care unit, LOS length of stay.
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tients’ stays in the ICU and hospital, and they had not
recovered to pre-contrast levels even at the time of
discharge from the ICU or hospital.
Twenty-nine of the CA-AKI patients already had renal
dysfunction before contrast use. The recovery of AKI at
hospital discharge was only 17%, and this was lower
compared with that seen on ICU discharge (25%). In
addition, high-severity subgroups based on the RIFLE
classification (Failure, Loss, and ESKD) constituted 45%
of the CA-AKI patients at the time of hospital discharge.
According to the RIFLE classification, patients with
CA-AKI progressed toward a more severe decrease in
kidney function, and it was found that renal function inFigure 2 Kaplan Meier plot. Kaplan–Meier plot show the survival after co
The survival of CA-AKI patients was significantly lower than the patients wi
Hosp = length of stay in hospital after contrast administration.CA-AKI was unlikely to recover compared with func-
tion prior to contrast use. This progress of CA-AKI
was also shown by the SCr and GFR changes. In an-
other report, patients with RIFLE class I or class F in-
curred a significantly increased length of stay and an
increased risk of hospital mortality compared with
those who did not progress past class R or those who
never developed AKI, even after adjusting for baseline
factors such as severity of illness, case mix, race, gen-
der, and age [1]. The RIFLE criteria afford a good op-
portunity for AKI researchers to compare the incidence
of AKI, early diagnosis of AKI, interventional studies to
prevent the development or to facilitate the recovery
process of AKI, and prediction of AKI outcomesntrast medium administration of patients with and without CA-AKI.
thout CA-AKI. CA-AKI = contrast-associated acute kidney injury, LOS
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simple tool for the detection and classification of AKI
and for correlation with clinical outcomes [18]. For
these reasons, we used the RIFLE classification to de-
scribe CA-AKI.
The APACHE II score was the only significant variable
in the development of CA-AKI in our study. The APA-
CHE II score is a tool used to determine patients’ sever-
ity of critical illness, and this scoring is widely used with
the Simplified Acute Physiology Score II in ICUs [2,6].
Although it is not clear whether the APACHE II score is
useful in clinical practice as a predictor of CA-AKI, it is
certain that the more critically ill the patients in ICUs
are, the more vulnerable they may be to AKI; thus, a
more active prevention and treatment is needed for
CA-AKI. In a recent study [19], the severity of disease
and the global nephrotoxic burden were risk factors for
AKI, regardless of iodinated CM infusion. The toxic ef-
fect of modern CM appeared minimal but because it
contributes to the overall nephrotoxic burden, prevent-
ive measures should still be considered at the time of
CM infusion, at least in high-risk patients. That is, ICU
patients have a higher severity of illness than general
hospital patients, and are more susceptible to CA-AKI.
Further research is needed for ICU populations such as
those in this study. Therefore, it is very important to
continue using known preventive procedures for CA-AKI,
but further research is needed to discover more effective
preventive methods. It is also important to improve the
overall conditions of ICU patients prior to testing with
contrast in order to reduce the severity of illness.
Risk factors for CA-AKI are understood for patients
undergoing percutaneous coronary angiography [20], but
have not been clarified in medical or surgical ICUs [6].
Our analysis identified risk factors that may assist in pre-
dicting patients at risk of developing CA-AKI in the ICU.
We compared two groups with and without CA-AKI
using conventional risk factors [16]. Preexisting renal im-
pairment, diabetes mellitus, advanced age, heart failure,
hypertension, and amount of CM used are important pre-
disposing factors after percutaneous coronary angiography
[21]. In our study, the influence of the volume of CM and
application of preventive measures, such as hydration and
N-acetylcysteine administration, were not associated with
the incidence of CA-AKI. The pathophysiology behind
CA-AKI is still not completely shown, although it is
thought that renal medullary hypoxia is pivotal to the
pathophysiology of CA-AKI [22]. Contrast medium in the
medulla affects the fragile balance between oxygen deliv-
ery and oxygen consumption through several mechanisms,
with the main mechanism being reduced blood perfusion
[23]. The molar concentration is a major determinant of
two important physicochemical properties of CM solu-
tions: osmolality and viscosity. According to some studies,regardless of CM type, the amount of CM a patient re-
ceives is a powerful predictor of CA-AKI [24,25]. Hy-
dration prevents CA-AKI by flushing the tubules, and
decreasing the CM dose diminishes tubular fluid vis-
cosity and cytotoxic effects [11]. Additionally, with the
possible exception of high-dose N-acetylcysteine [26],
no treatment has been unequivocally proven efficient
in reducing the CA-AKI risk, and in fact endothelin
antagonists may have detrimental effects [27,28].
In our study, the rate of RRT and LOS in the ICU and
hospital after contrast use did not show any significant
difference. Rihal’s group reported that the risk of RRT,
ICU and hospital LOS, and mortality were increased in
non-ICU patients developing CA-AKI [26]. Additionally,
this risk was higher compared with the incidence of RRT
in non-ICU patients with CA-AKI in other studies
[9,29]. In our study, the mortality—including in the ICU,
hospital, and overall—in CA-AKI patients was higher
than seen in previous studies evaluating the prognosis of
AKI as defined by the RIFLE criteria [2,18]. In addition,
the survival rate of LOS in the hospital after contrast
use was significantly reduced for patients with AKI. The
reasons for the high mortality rate for CA-AKI could be
due to two possibilities: the shortage of aggressive pre-
vention and management for CA-AKI, or the fact that
the prognosis of patients with renal failure is poor re-
gardless of contrast use [10].
Our results have several limitations for clinical appli-
cation to other ICU populations. First, our study was a
retrospective analysis at a single center. It may fail to
identify patients’ selection biases. The study also had a
small sample size. Second, we identified the predictor
for CA-AKI as APACHE II but it was not clear whether
the CA-AKI was caused by contrast administration, the
underlying disease, or both, as AKI may indeed be multi-
factorial in critically ill patients. Third, we did not investi-
gate further long-term outcomes associated with survival
rate based on the administrative patients’ data.
Despite these limitations, we have reported the first
significant result in ICU patients to identify the onset
and progress of CA-AKI using the RIFLE classification
after contrast administration during their stay in the
ICU and hospital. We believe our study can provide im-
portant advice for a prospective study on CA-AKI in
ICUs, including the incidence, relevant risk factors, and
further predictors for CA-AKI, and outcomes, resulting
in more effective prevention methods.
Conclusions
The incidence of CA-AKI determined using the RIFLE
criteria was 15.5%, and the onset of CA-AKI was within
48 hours after CM administration. The level of creatin-
ine peaked at 72 hours after use, and the recovery rate
of the CA-AKI patients as assessed by the RIFLE
Kim et al. BMC Anesthesiology  (2015) 15:23 Page 8 of 8classification was poor. The APACHE II score was asso-
ciated with CA-AKI, and CA-AKI was associated with
higher mortality in the ICU and hospital. Therefore,
while it is helpful to apply thorough preventive mea-
sures, such as hydration and N-acetylcysteine adminis-
tration, in high-risk patients before using CM, further
studies are needed to investigate CA-AKI epidemiology,
prophylactic strategies, and long-term follow-up of out-
comes in critically ill patients in the ICU.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
MHK made substantial contributions to the design and conduct of the study,
analysis of the data, and writing of the manuscript. SWN made substantial
contributions to the analysis of the data and writing of the manuscript. SOK
made substantial contributions to the study design and conduct of the
study. EJK and JSC made substantial contributions to the conduct of the
study. All authors have read and approved the final manuscript.
Acknowledgments
We thank the electronic medical record team in Severance Hospital, College
of Medicine, Yonsei University for their contribution to this study. The
authors declare no financial support or sponsorship.
Author details
1Department of Anesthesiology and Pain Medicine, Anesthesia and Pain
Research Institute, Yonsei University College of Medicine, 50 Yonsei-ro,
Seodaemun-gu, Seoul 120-752, Republic of Korea. 2Department of
Anesthesiology and Pain Medicine, Chung-Ang University College of Medine,
Seoul, Republic of Korea.
Received: 15 July 2014 Accepted: 20 February 2015
References
1. Hoste EA, Clermont G, Kersten A, Venkataraman R, Angus DC, De Bacquer D,
et al. RIFLE criteria for acute kidney injury are associated with hospital
mortality in critically ill patients: a cohort analysis. Crit Care. 2006;10(3):R73.
2. Clec’h C, Razafimandimby D, Laouisset M, Chemouni F, Cohen Y. Incidence and
outcome of contrast-associated acute kidney injury in a mixed medical-surgical
ICU population: a retrospective study. BMC Nephrol. 2013;14:31.
3. Seeliger E, Sendeski M, Rihal CS, Persson PB. Contrast-induced kidney injury:
mechanisms, risk factors, and prevention. Eur Heart J. 2012;33(16):2007–15.
4. Haveman JW, Gansevoort RT, Bongaerts AH, Nijsten MW. Low incidence of
nephropathy in surgical ICU patients receiving intravenous contrast: a
retrospective analysis. Intensive Care Med. 2006;32(8):1199–205.
5. Polena S, Yang S, Alam R, Gricius J, Gupta JR, Badalova N, et al.
Nephropathy in critically Ill patients without preexisting renal disease. Proc
West Pharmacol Soc. 2005;48:134–5.
6. Rashid AH, Brieva JL, Stokes B. Incidence of contrast-induced nephropathy in
intensive care patients undergoing computerised tomography and prevalence
of risk factors. Anaesth Intensive Care. 2009;37(6):968–75.
7. Huber W, Jeschke B, Page M, Weiss W, Salmhofer H, Schweigart U, et al.
Reduced incidence of radiocontrast-induced nephropathy in ICU patients
under theophylline prophylaxis: a prospective comparison to series of patients
at similar risk. Intensive Care Med. 2001;27(7):1200–9.
8. Huber W, Eckel F, Hennig M, Rosenbrock H, Wacker A, Saur D, et al. Prophylaxis of
contrast material-induced nephropathy in patients in intensive care:
acetylcysteine, theophylline, or both? A randomized study. Radiology.
2006;239(3):793–804.
9. Uchino S, Kellum JA, Bellomo R, Doig GS, Morimatsu H, Morgera S, et al.
Acute renal failure in critically ill patients: a multinational, multicenter study.
JAMA. 2005;294(7):813–8.
10. Bagshaw SM, Laupland KB, Doig CJ, Mortis G, Fick GH, Mucenski M, et al.
Prognosis for long-term survival and renal recovery in critically ill patients
with severe acute renal failure: a population-based study. Crit Care.
2005;9(6):R700–9.11. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. Acute dialysis quality
initiative w: Acute renal failure - definition, outcome measures, animal models,
fluid therapy and information technology needs: the Second International
Consensus Conference of the Acute Dialysis Quality Initiative (ADQI)
Group. Crit Care. 2004;8(4):R204–12.
12. Sigurdsson MI, Vesteinsdottir IO, Sigvaldason K, Helgadottir S, Indridason OS,
Sigurdsson GH. Acute kidney injury in intensive care units according to
RIFLE classification: a population-based study. Acta Anaesthesiol Scand.
2012;56(10):1291–7.
13. Garcia S, Ko B, Adabag S. Contrast-induced nephropathy and risk of acute
kidney injury and mortality after cardiac operations. Ann Thorac Surg.
2012;94(3):772–6.
14. Neyra JA, Shah S, Mooney R, Jacobsen G, Yee J, Novak JE. Contrast-induced
acute kidney injury following coronary angiography: a cohort study of
hospitalized patients with or without chronic kidney disease. Nephrol Dial
Transplant. 2013;28(6):1463–71.
15. Hoste EA, Doom S, De Waele J, Delrue LJ, Defreyne L, Benoit DD, et al.
Epidemiology of contrast-associated acute kidney injury in ICU patients: a
retrospective cohort analysis. Intensive Care Med. 2011;37(12):1921–31.
16. Srisawat N, Hoste EE, Kellum JA. Modern classification of acute kidney injury.
Blood Purif. 2010;29(3):300–7.
17. Uchino S, Bellomo R, Goldsmith D, Bates S, Ronco C. An assessment of the
RIFLE criteria for acute renal failure in hospitalized patients. Crit Care Med.
2006;34(7):1913–7.
18. Bagshaw SM, George C, Dinu I, Bellomo R. A multi-centre evaluation of the
RIFLE criteria for early acute kidney injury in critically ill patients. Nephrol
Dial Transplant. 2008;23(4):1203–10.
19. Ehrmann S, Badin J, Savath L, Pajot O, Garot D, Pham T, et al. Acute kidney
injury in the critically ill: is iodinated contrast medium really harmful? Crit
Care Med. 2013;41(4):1017–26.
20. Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M, et al. A simple
risk score for prediction of contrast-induced nephropathy after percutaneous
coronary intervention: development and initial validation. J Am Coll Cardiol.
2004;44(7):1393–9.
21. Rihal CS, Textor SC, Grill DE, Berger PB, Ting HH, Best PJ, et al. Incidence and
prognostic importance of acute renal failure after percutaneous coronary
intervention. Circulation. 2002;105(19):2259–64.
22. Tumlin J, Stacul F, Adam A, Becker CR, Davidson C, Lameire N, et al.
Pathophysiology of contrast-induced nephropathy. Am J Cardiol.
2006;98(6a):14k–20.
23. Heyman SN, Rosen S, Rosenberger C. Renal parenchymal hypoxia, hypoxia
adaptation, and the pathogenesis of radiocontrast nephropathy. Clin J Am
Soc Nephrol. 2008;3(1):288–96.
24. Kane GC, Doyle BJ, Lerman A, Barsness GW, Best PJ, Rihal CS. Ultra-low contrast
volumes reduce rates of contrast-induced nephropathy in patients with
chronic kidney disease undergoing coronary angiography. J Am Coll Cardiol.
2008;51(1):89–90.
25. Marenzi G, Assanelli E, Campodonico J, Lauri G, Marana I, De Metrio M, et al.
Contrast volume during primary percutaneous coronary intervention and
subsequent contrast-induced nephropathy and mortality. Ann Intern Med.
2009;150(3):170–7.
26. Briguori C, Marenzi G. Contrast-induced nephropathy: pharmacological
prophylaxis. Kidney Int Suppl. 2006;100:S30–8.
27. Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC. Meta-analysis:
effectiveness of drugs for preventing contrast-induced nephropathy.
Ann Intern Med. 2008;148(4):284–94.
28. Stacul F, van der Molen AJ, Reimer P, Webb JA, Thomsen HS, Morcos SK,
et al. Contrast induced nephropathy: updated ESUR Contrast Media Safety
Committee guidelines. Eur Radiol. 2011;21(12):2527–41.
29. Hoste EA, Schurgers M. Epidemiology of acute kidney injury: how big is the
problem? Crit Care Med. 2008;36(4 Suppl):S146–51.
